Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in ...

However, testing for a complex karyotype is important because it provides ... and about 20% had previously received a PI3K inhibitor. The response rates are similar across several key clinical factors ...

A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

Future Virology. 2012;7(11):1089-1101. Patients with advanced fibrosis or cirrhosis treated with PI triple therapy also showed diminished SVR rates, possibly related to reduced IFN responsiveness ...

With the publication of this study, guselkumab is now the third IL-23 inhibitor to meet its primary efficacy endpoint in this population, joining the already approved mirikizumab and risankizumab. 3,4 ...

The development of targeted therapies using tyrosine kinase inhibitors and immunotherapies has significantly ... protein kinase), phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT), PLCγ, and ...

Combined MEK and PI3K inhibition has had limited success in the clinic, although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple ...